A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-28 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Crick was interested in two fundamental unsolved problems of biology: how molecules make the transition from the non-living to the living, and how the brain makes a conscious mind. He realised that his background made him more qualified for research on the first topic and the field of biophysics. In 1946 Crick read Erwin Schrödinger's book, What Is Life? and was influenced by it, and Linus Pauling, to switch from physics to biology. It was clear in theory that covalent bonds in biological molecules could provide the structural stability needed to hold genetic information in cells. It only remained as an exercise of experimental biology to discover exactly which molecule was the genetic molecule. In Crick's view, Charles Darwin's theory of evolution by natural selection, Gregor Mendel's genetics and knowledge of the molecular basis of genetics, when combined, revealed the secret of life. Crick had the very optimistic view that life would very soon be created in a test tube. However, some people (such as fellow researcher and colleague Esther Lederberg) thought that Crick was unduly optimistic. It was clear that some macromolecule such as a protein was likely to be the genetic molecule. However, it was well known that proteins are structural and functional macromolecules, some of which carry out enzymatic reactions of cells. In the 1940s, some evidence had been found pointing to another macromolecule, DNA, the other major component of chromosomes, as a candidate genetic molecule.
A mixed dose commonly combines regular insulin, which is fast acting, with a longer acting insulin such as NPH. A mixed dose insulin schedule may be prescribed to provide both short-term and long-term coverage. mmol/L Millimoles per litre. The world-standard (excepting the US) designated SI unit for the measurement of blood sugar levels. It is the concentration by molecular weight in a set amount of liquid. Mononeuropathy A form of diabetic neuropathy affecting a single nerve. The eye is a common site for this form of nerve damage. See also: Neuropathy. Morbidity rate the rate at which Mortality rate the rate at which death occurs (usually used as a statistical shorthand in regard to an infection or other condition). Myocardial infarction heart attack. The words mean heart muscle blockage. Myo-inositol A substance in the cell that is thought to play a role in helping the nerves to work. Low levels of myo-inositol may be involved in diabetic neuropathy.
== Civilian applications == Depleted uranium has a very high density and is primarily used as shielding material for other radioactive material, and as ballast. Examples include sailboat keels, as counterweights and as shielding in industrial radiography cameras.
Sources: en.wikipedia.org
United Nations Security Council Resolution 283 was passed in June 1970 calling for all UN member states to close, or refrain from establishing, diplomatic or consular offices in South West Africa. The resolution also recommended disinvestment, boycotts, and voluntary sanctions of that territory as long as it remained under South African rule. In light of these developments, the Security Council sought the advisory opinion of the ICJ on the "legal consequences for states of the continued presence of South Africa in Namibia". There was initial opposition to this course of action from SWAPO and the OAU, because their delegates feared another inconclusive ruling like the one in 1966 would strengthen South Africa's case for annexation. Nevertheless, the prevailing opinion at the Security Council was that since the composition of judges had been changed since 1966, a ruling in favour of the nationalist movement was more likely. At the UN's request, SWAPO was permitted to lobby informally at the court and was even offered an observer presence in the courtroom itself. On 21 June 1971, the ICJ reversed its earlier decision not to rule on the legality of South Africa's mandate, and expressed the opinion that any continued perpetuation of said mandate was illegal. Furthermore, the court found that Pretoria was under obligation to withdraw its administration immediately and that if it failed to do so, UN member states would be compelled to refrain from any political or business dealings which might imply recognition of the South African government's presence there.
=== Early days of Pentagram === Though Pentagram struggled with lineup changes and financial issues, the band became a key influence in the development of doom metal, with Liebling's distinct vocals and songwriting playing a major role in their cult following. Their early recordings, particularly Relentless (1985) and Day of Reckoning (1987), laid the groundwork for future doom metal acts. Despite their potential, Liebling's struggles with substance abuse, internal conflicts, and frequent lineup changes prevented Pentagram from achieving stability and mainstream success. By the mid-1970s, the band had caught the attention of influential managers and producers. One such figure was Gordon Fletcher, a columnist for Rolling Stone and Creem, who connected them with Sandy Pearlman and Murray Krugman, producers and managers of Blue Öyster Cult. Pentagram had an opportunity to record a full album, but the deal collapsed when Liebling, dissatisfied with the production of one of his tracks, had a heated argument with Krugman. As a result, Krugman walked out, canceling their contract. Gene Simmons and Paul Stanley of Kiss were invited to a Pentagram rehearsal, with hopes of impressing them and securing their mentorship. However, guitarist Vince McAllister and bassist Greg Mayne, who at the time were janitors, arrived late, still in their dirty uniforms from work. The Kiss members mocked their appearance rather than taking the band seriously. Despite this, Paul Stanley offered to purchase some of their songs, but Liebling refused, wanting to keep control of his material.
=== Uniqueness of venom === Centipede venom generally contains a few different enzymes that are very different from other arthropods, where metalloprotease, an enzyme that breaks down protein plays an important role. Centipede venom has effects on skeletal muscles, heart muscles, and neurons, and the effects are attributed to the larger protein molecules in the venom. Venoms of S. mutilans contain a diverse range of neurotoxins, including 26 neurotoxin-like peptides that belong to 10 different groups. Most of the 26 identified neurotoxin-like peptides have a different molecular structure compared to the neurotoxins found in spiders, snakes, scorpions, marine cone snails, and sea anemones. The functional mechanism of these peptides are similar to the neurotoxins of the mention venomous animals, yet their primary structures remain unique. A few were found to contain insecticidal properties and act on voltage-gated sodium, potassium, and calcium channels. It was found that both purified neurotoxins and unprocessed centipede venom are highly insecticidal, with the unprocessed venom being significantly stronger than all purified neurotoxins in insecticidal effects. Centipede venoms might have the potential to provide peptide candidates with potential pharmaceutical or agrochemical uses due to their high level of biochemical diversity.
=== The cell === A standard CV experiment employs a cell fitted with three electrodes: reference electrode, working electrode, and counter electrode. This combination is sometimes referred to as a three-electrode setup. Electrolyte is usually added to the sample solution to ensure sufficient conductivity. The solvent, electrolyte, and material composition of the working electrode will determine the potential range that can be accessed during the experiment. The electrodes are immobile and sit in unstirred solutions during cyclic voltammetry. This "still" solution method gives rise to cyclic voltammetry's characteristic diffusion-controlled peaks. This method also allows a portion of the analyte to remain after reduction or oxidation so that it may display further redox activity. Stirring the solution between cyclic voltammetry traces is important in order to supply the electrode surface with fresh analyte for each new experiment. The solubility of an analyte can change drastically with its overall charge; as such it is common for reduced or oxidized analyte species to precipitate out onto the electrode. This layering of analyte can insulate the electrode surface, display its own redox activity in subsequent scans, or otherwise alter the electrode surface in a way that affects the CV measurements. For this reason it is often necessary to clean the electrodes between scans. Common materials for the working electrode include glassy carbon, platinum, and gold. These electrodes are generally encased in a rod of inert insulator with a disk exposed at one end.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.